logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

eBCa: denosumab fails to improve survival of high-risk patients in D-CARE

Phase 3 trial of 4000 women randomly assigned to denosumab or placebo.